European Commission Approves Roche’s Tecentriq SC, the EU’s First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Until now, Tecentriq has been given directly into patients’ veins by IV infusion which takes approximately 30-60 minutes. The new subcutaneous injection will cut treatment time to approximately seven minutes, with most injections taking between four and eight minutes.